In order to validate the correlation between MYC transcriptional signature and clinical response to PARPis, we analyzed 12 paraffin-embedded pre-PARPi treatment biopsies of patients with metastatic HR-altered breast cancer who were subsequently included in a clinical trial with PARPis (Figures S6A and S6B). This evidence concerns the gene MYC and breast cancer.